Vaccine Info

Bexsero Meningitis B Vaccine

Authored by
Last reviewed
March 30, 2021

Bexsero Meningitis B Vaccine Description

Bexsero vaccine contains different proteins taken from group B Neisseria meningitidis bacteria. The combination of proteins was chosen to protect against the majority of MenB strains. 

Apart from these active ingredients, the vaccine contains very small amounts of these ingredients: Aluminium which strengthens and lengthens the immune response to the vaccine, salt (sodium chloride), sugar (sucrose), and an amino acid called histidine, both used as acidity regulators. Anyone who is allergic to these ingredients or who had a severe allergic reaction after a previous dose should not receive BEXSERO.

On December 1, 2020, in a matched case-control study published by the JAMA that included 299 children, the likelihood of full vaccination with 4CMenB among children old enough to be fully immunized was significantly lower among cases with group B invasive meningococcal disease compared with controls without the invasive meningococcal disease (odds ratio, 0.21).

Of 11 children with meningococcal infection who had received at least one dose of the 4CMenB vaccine, all survived, and none were left with related disabilities. In contrast, among the remaining 87 cases who were unvaccinated, seven died and 16 suffered long-term injuries, suggesting that the vaccinated cases may have been partially protected.

This finding means during the first 5 years of vaccine availability in Portugal, full vaccination with 4CMenB was less likely among children who developed group B invasive meningococcal disease compared with matched controls.

Researcher Professor Finn added: "Although rare, meningococcus group B infection can become life-threatening within hours and can cause long-term disabilities. Young children, in particular, are more at risk and may die or be seriously harmed even with top-quality hospital treatment. This important new study confirms that 4CMenB offers children a very high level of protection against suffering severe outcomes from this potentially deadly infection."

GSK is the producer of Bexsero.

Bexsero Meningitis B Vaccine Indication

Bexsero is an FDA-approved vaccine to prevent invasive disease caused by Neisseria meningitidis serogroup B. Bexsero was approved for use in 2014 for individuals 10 through 25 years of age.

Meningococcal B vaccine can help protect against meningococcal disease caused by serogroup B.  A different meningococcal vaccine is available that can help protect against serogroups A, C, W, and Y says the U.S. CDC.

Bexsero Meningitis B Vaccine Dosage

Bexsero is for intramuscular use only. The 2 doses of Bexsero can be completed in 1 month.

Bexsero Meningitis B Vaccine News

December 1, 2020 - Meningococcus group B, the most prevalent strain of meningococcal infection, is prevented with 79% effectiveness in children and young adults inoculated with the 4CMenB vaccine, also known as Bexsero, according to a new collaborative study from researchers in Portugal and the UK and led by the University of Bristol which evaluated the vaccine's performance in a real-world setting.

Clinical Trials

No clinical trials found